This study is designed to evaluate safety and assess initial efficacy of VX-509, a JAK3 inhibitor, for treatment of subjects with active RA. This study will assess the clinical response of 4 doses of VX-509 compared to placebo when administered for 12 weeks to patients with active RA. The study will also evaluate the safety and tolerability of VX-509 compared to placebo when administered for 12 weeks to subjects with active RA.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01052194?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
